On a scale from 1-10 (10 being extremely excited), how excited are you about the Phase 2 data for APG777?

How many patients do you manage for atopic dermatitis?

APG777 achieved an EASI-75 rate of 66.9% at Week 16 — the highest reported in a global biologic trial for AD to date. How significant is this result when viewed against historical benchmarks like Dupixent or tralokinumab, and what does it imply for positioning in the biologic treatment landscape?

The data showed that patients in the highest exposure quartile reached EASI-75 response rates up to 89.5%. How should we interpret this exposure-response trend, and what are the clinical and pharmacological implications for dosing optimization in Part B and Phase 3?

A statistically significant reduction in itch (Itch NRS) was observed by Week 1. How meaningful is such rapid symptom control for long-term disease management and patient adherence, especially in comparison to slower-acting agents?

With APEX Part A testing 3- and 6-month maintenance dosing schedules, what are the potential advantages — and risks — of stretching biologic dosing intervals to quarterly or biannual injections in AD, particularly in terms of disease control and healthcare system costs?

Across multiple endpoints, APG777 demonstrated high placebo-adjusted response rates — over 42% for EASI-75 and approximately 19–20% for vIGA 0/1 and EASI-90. How important is this magnitude of difference in regulatory submissions and payer negotiations?

APG777 reported zero injection site reactions and fewer respiratory infections than placebo. How notable is this in the context of patient experience and safety differentiation, and could it influence preference in the clinic?

With APG279 now entering a Phase 1b head-to-head trial against Dupixent, what are the key endpoints and differentiators you would prioritize in order to credibly challenge the current standard of care in the IL-4/IL-13 pathway?

Given the strength of the Part A data and accelerated readout timelines for Part B, what would you consider critical design elements or strategic risks to watch in the upcoming Phase 3 trial, particularly to ensure global regulatory success?

How is APG777 different from MoAs in AD? How significant is this difference to you as a provider?

How do you see potentially using APG777 vs. the current SOC (if approved)?